Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 28, 2026, 1:04 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1033–1056 of 1,834 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Placebo- C Clear all
Completed Early Phase 1 Interventional Accepts healthy volunteers

Investigating Oral Agents for Urine Staining to Facilitate Intraoperative Observation of Ureteral Jets

NCT03432572
View directory record Official record
Conditions
Ureteral Injury
Interventions
Pyridium, Riboflavin, Thiamine
Drug
Lead sponsor
Texas Tech University Health Sciences Center
Other
Eligibility
21 Years to 75 Years · Female only
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
1
States / cities
Lubbock, Texas
Source: ClinicalTrials.gov public record
Updated Aug 11, 2020 · Synced Oct 28, 2026, 1:04 PM EDT
Completed Phase 3 Interventional

Whole-Body Cooling for Birth Asphyxia in Term Infants

NCT00005772
View directory record Official record
Conditions
Infant, Newborn, Hypoxia-Ischemia, Brain
Interventions
Induced hypothermia, Control
Device
Lead sponsor
NICHD Neonatal Research Network
Network
Eligibility
Up to 6 Hours
Enrollment
208 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2010
U.S. locations
16
States / cities
Birmingham, Alabama • Palo Alto, California • New Haven, Connecticut + 13 more
Source: ClinicalTrials.gov public record
Updated Mar 22, 2019 · Synced Oct 28, 2026, 1:04 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluation of a 3-dose Vaccination Regimen With One of Three Ascending Dose Levels of Clostridium Difficile Vaccine With or Without Adjuvant in Healthy Adults Aged 50 to 85 Years

NCT01706367
View directory record Official record
Conditions
Clostridium Difficile Associated Disease
Interventions
C. difficile vaccine, C. difficile vaccine +adjuvant
Biological
Lead sponsor
Pfizer
Industry
Eligibility
50 Years to 85 Years
Enrollment
192 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2014
U.S. locations
4
States / cities
Pembroke Pines, Florida • South Miami, Florida • Overland Park, Kansas + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 6, 2014 · Synced Oct 28, 2026, 1:04 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Gender, Obesity, C-Reactive Protein, and Oxidative Stress

NCT00079963
View directory record Official record
Conditions
Cardiovascular Disease
Interventions
Vitamin C, Vitamin E, Placebo
Dietary Supplement
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
18 Years and older
Enrollment
396 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2008
U.S. locations
1
States / cities
Berkeley, California
Source: ClinicalTrials.gov public record
Updated Sep 27, 2017 · Synced Oct 28, 2026, 1:04 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase 1 TP-271 Oral PK Multiple Ascending Dose Study

NCT03450187
View directory record Official record
Conditions
Bacterial Infections
Interventions
TP-271
Drug
Lead sponsor
Tetraphase Pharmaceuticals, Inc
Industry
Eligibility
18 Years to 50 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Dec 17, 2021 · Synced Oct 28, 2026, 1:04 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety of and Immune Response to Two HIV Vaccines: SAAVI DNA-C2 Boosted With SAAVIMVA-C, in HIV-Negative Adults

NCT00574600
View directory record Official record
Conditions
HIV Infections
Interventions
SAAVI DNA-C2 vaccine, SAAVI MVA-C vaccine, Placebo
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 45 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2013
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 14, 2021 · Synced Oct 28, 2026, 1:04 PM EDT
Terminated Phase 3 Interventional Results available

Study to Evaluate the Efficacy, Safety and Tolerability of an Oral Aripiprazole/Escitalopram Combination Therapy in Participants With Major Depressive Disorder (MDD)

NCT01111552
View directory record Official record
Conditions
Major Depressive Disorder (MDD)
Interventions
Escitalopram, Aripiprazole, Placebo
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
237 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
20
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Carson, California + 16 more
Source: ClinicalTrials.gov public record
Updated Oct 26, 2021 · Synced Oct 28, 2026, 1:04 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase 1 Study of ONO-2020 in Healthy Participants

NCT05507515
View directory record Official record
Conditions
Healthy Volunteers
Interventions
ONO-2020, Placebo
Drug
Lead sponsor
Ono Pharmaceutical Co., Ltd.
Industry
Eligibility
18 Years and older
Enrollment
132 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Cypress, California
Source: ClinicalTrials.gov public record
Updated Apr 9, 2024 · Synced Oct 28, 2026, 1:04 PM EDT
Recruiting Phase 3 Interventional

A Clinical Trial of Adjuvant Intismeran (V940) With or Without Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) in High-Risk Stage I Non-Small Cell Lung Cancer (V940-014)

NCT07513376
View directory record Official record
Conditions
Non-small Cell Lung Cancer
Interventions
Intismeran, Pembrolizumab coformulated with berahyaluronidase alfa, Placebo
Biological · Other
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
876 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2038
U.S. locations
24
States / cities
Sacramento, California • Aurora, Colorado • New Haven, Connecticut + 20 more
Source: ClinicalTrials.gov public record
Updated Oct 19, 2026 · Synced Oct 28, 2026, 1:04 PM EDT
Completed Not applicable Interventional

Study to Evaluate Benefits & Safety of Endourage Formula C™ Oral Drops in People With Post-Acute COVID-19 Syndrome.

NCT04828668
View directory record Official record
Conditions
Covid 19
Interventions
Targeted Wellness Formula C™ Sublingual Drops - 1200mg - 30 mL (Formula C)
Dietary Supplement
Lead sponsor
Endourage, LLC
Industry
Eligibility
18 Years to 75 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Novato, California
Source: ClinicalTrials.gov public record
Updated Aug 7, 2025 · Synced Oct 28, 2026, 1:04 PM EDT
Completed Phase 3 Interventional

Study to Assess Safety and Efficacy of Tenapanor for Treatment of IBS-C in Pediatric Patients 12 to Less Than 18 Years

NCT05643534
View directory record Official record
Conditions
Irritable Bowel Syndrome With Constipation (IBS-C)
Interventions
Tenapanor 50 MG, Tenapanor 25 mg bid, Placebo
Drug
Lead sponsor
Ardelyx
Industry
Eligibility
12 Years to 17 Years
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
39
States / cities
Foley, Alabama • Tucson, Arizona • Little Rock, Arkansas + 34 more
Source: ClinicalTrials.gov public record
Updated Sep 22, 2026 · Synced Oct 28, 2026, 1:04 PM EDT
Terminated Phase 1 Interventional

Study of Intramuscular Injections of ABBV-950 to Assess Adverse Events and Change in Disease Activity in Adult Participants With Upper Limb Spasticity

NCT05956509
View directory record Official record
Conditions
Upper Limb Spasticity
Interventions
ABBV-950, BOTOX, Placebo for ABBV-950
Biological · Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 80 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
9
States / cities
Carlsbad, California • Downey, California • Fresno, California + 6 more
Source: ClinicalTrials.gov public record
Updated Jul 1, 2024 · Synced Oct 28, 2026, 1:04 PM EDT
Active, not recruiting Phase 3 Interventional

Lp(a) Lowering Study of Pelacarsen (TQJ230) With Background Inclisiran in Participants With Elevated Lp(a) and Established ASCVD

NCT06813911
View directory record Official record
Conditions
Atherosclerotic Cardiovascular Disease (ASCVD)
Interventions
Pelacarsen, Placebo, Inclisiran
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 80 Years
Enrollment
246 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
35
States / cities
Birmingham, Alabama • Sun City West, Arizona • Beverly Hills, California + 31 more
Source: ClinicalTrials.gov public record
Updated Oct 14, 2026 · Synced Oct 28, 2026, 1:04 PM EDT
Completed Phase 1 Interventional

A Study to Evaluate the Effect of JNJ-28431754 (Canagliflozin) on Post-Meal Glucose in Patients With Type 2 Diabetes Mellitus

NCT01381887
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Placebo, Canagliflozin 300mg/Placebo, Canagliflozin 300mg/Canagliflozin 150mg, Canagliflozin 300mg
Drug
Lead sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Industry
Eligibility
25 Years to 70 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
5
States / cities
Chula Vista, California • Miramar, Florida • Cincinnati, Ohio + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 22, 2013 · Synced Oct 28, 2026, 1:04 PM EDT
Active, not recruiting Phase 3 Interventional

A Phase III Study to Assess the Effect of AZD0780 on LDL-C in Patients With HeFH

NCT07000136
View directory record Official record
Conditions
Heterozygous Familial Hypercholesterolaemia
Interventions
AZD0780, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
473 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
19
States / cities
Garden Grove, California • San Diego, California • Miami Lakes, Florida + 16 more
Source: ClinicalTrials.gov public record
Updated Jul 16, 2026 · Synced Oct 28, 2026, 1:04 PM EDT
Recruiting Phase 2 Interventional

A Study to Evaluate Mivelsiran in Adult Participants With Early-Stage Down Syndrome-Associated Alzheimer's Disease (DS-AD)

NCT07636811
View directory record Official record
Conditions
Down Syndrome-Associated Alzheimer's Disease (DS-AD)
Interventions
Mivelsiran, Placebo
Drug
Lead sponsor
Alnylam Pharmaceuticals
Industry
Eligibility
40 Years to 55 Years
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
4
States / cities
Maitland, Florida • Naples, Florida • Indianapolis, Indiana + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 28, 2026, 1:04 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Two-part, Single-dose, Randomized Study to Evaluate the Safety of Supra-therapeutic Doses of RO7033877 and to Investigate the Effect of RO7033877 on the QTc Interval

NCT02165332
View directory record Official record
Conditions
Healthy Volunteer
Interventions
Part 1: SAD RO7033877, Part 1: SAD placebo, Part 2: Treatment A, RO7033877, Part 2: Treatment B, RO7033877, Part 2: Treatment C, moxifloxacin, Part 2: Treatment D, RO7033877 and moxifloxacin placebo
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 65 Years
Enrollment
64 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Lenexa, Kansas
Source: ClinicalTrials.gov public record
Updated Nov 2, 2016 · Synced Oct 28, 2026, 1:04 PM EDT
Completed Phase 2 Interventional Results available

Minocycline Hydrochloride in Reducing Chemotherapy Induced Depression and Anxiety in Patients With Stage I-III Breast Cancer

NCT02203552
View directory record Official record
Conditions
Anxiety Disorder, Depression, Recurrent Breast Cancer, Stage IA Breast Cancer, Stage IB Breast Cancer, Stage II Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer
Interventions
minocycline hydrochloride, placebo, laboratory biomarker analysis, Questionnaire administration
Drug · Other
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 8, 2025 · Synced Oct 28, 2026, 1:04 PM EDT
Completed Phase 2 Interventional

Phase 2b Study to Investigate the Safety and Efficacy of TIN816 in Sepsis-associated Acute Kidney Injury (CLEAR-AKI)

NCT05996835
View directory record Official record
Conditions
Acute Kidney Injury Due to Sepsis
Interventions
TIN816 70 mg lyophilisate powder, Placebo
Biological · Other
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 85 Years
Enrollment
316 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
19
States / cities
Birmingham, Alabama • San Francisco, California • Stanford, California + 14 more
Source: ClinicalTrials.gov public record
Updated Jul 29, 2026 · Synced Oct 28, 2026, 1:04 PM EDT
Completed Phase 3 Interventional Results available

A Study of Ipatasertib in Combination With Atezolizumab and Paclitaxel as a Treatment for Participants With Locally Advanced or Metastatic Triple-Negative Breast Cancer

NCT04177108
View directory record Official record
Conditions
Triple-Negative Breast Cancer
Interventions
Atezolizumab, Ipatasertib, Paclitaxel, Placebo for Atezolizumab, Placebo for Ipatasertib
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
242 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
31
States / cities
Mobile, Alabama • Springdale, Arkansas • Los Angeles, California + 25 more
Source: ClinicalTrials.gov public record
Updated Mar 27, 2024 · Synced Oct 28, 2026, 1:04 PM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of Intravenous ACZ885 and Oral Methotrexate Therapy in Patients With Early Rheumatoid Arthritis

NCT00487825
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Canakinumab (investigational), Placebo, Methotrexate (MTX)
Drug
Lead sponsor
Novartis
Industry
Eligibility
18 Years to 75 Years
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
17
States / cities
Huntsville, Alabama • Tuscaloosa, Alabama • Paradise Valley, Arizona + 14 more
Source: ClinicalTrials.gov public record
Updated Aug 1, 2012 · Synced Oct 28, 2026, 1:04 PM EDT
Active, not recruiting Phase 4 Interventional

Polygenic Risk-based Detection of Subclinical Coronary Atherosclerosis and Intervention With Statin and Colchicine

NCT05850091
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
Rosuvastatin, Colchicine, Placebo
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
40 Years to 75 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 12, 2026 · Synced Oct 28, 2026, 1:04 PM EDT
Completed No phase listed Observational

Intraocular Pressure During Spine Surgery

NCT00593359
View directory record Official record
Conditions
Intraocular Pressure
Interventions
Not listed
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years to 80 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 23, 2016 · Synced Oct 28, 2026, 1:04 PM EDT
Completed Phase 1 Interventional

The Physiological Responses and Adaptation of Brown Adipose Tissue to Chronic Treatment With Beta3-Adrenergic Receptor Agonists

NCT03049462
View directory record Official record
Conditions
Polycystic Ovary Syndrome
Interventions
Mirabegron, B Complex Plus Vitamin C Tablets
Drug · Other
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
18 Years to 40 Years
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2026
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Oct 28, 2026, 1:04 PM EDT